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Symptomatic adult parvovirus B 19 infection typically
causes a brief arthritis, often with a rash. Persistent
symptoms may occur,' and B19 has been linked with
many rheumatic diseases. Virus specific IgM is detect-
able for about three months after infection, leaving a
narrow window in which to make a diagnosis when
chronic symptoms arise. Since blood samples from
patients with musculoskeletal disease are frequently
tested for rheumatoid factor we sought B19 DNA by
polymerase chain reaction in such samples in order to
identify any relation between chronic symptoms and
parvovirus infection.
Subjects, methods, and results
Remaining serum from 503 consecutive samples
submitted for a rheumatoid factor test was collected
prospectively between December 1992 and February
1993. Samples from blood donors (348) and from
inpatients requiring blood transfusions (333), also
collected during these months, served as controls.
Clinical data were obtained retrospectively from
records. B19 DNA was identified using a method
for screening large numbers of samples.2
Parvovirus DNA was found in 23 test samples and
two control samples. Samples submitted from general
practitioners were more likely to be positive (table). All
samples positive for B19 DNA and 48 negative samples
were tested for IgG and IgM by an indirect fluorescent
antibody technique.' The proportion of samples posi-
tive for rheumatoid factor (, 1/16) was similar in B19
DNA positive patients (3) to that for Bl9 negative
patients (53) (P=098).
Of the 23 patients with B19 DNA 17 had typical
joint pain resolving within one month (seven also had a
rash); two, known to have longstanding intermittent
seronegative arthritis, experienced an exacerbation
and were both IgM positive; one had an illness lasting
four months diagnosed as myalgic encephalitis; one
had carpal tunnel syndrome; one had intermittent
fatigue and neutropenia over many months; and one
was lost to follow up. Clinical diagnoses for samples
Details of patients and controls, presence of B19 DNA, and results of serological testing
Subjects B19 DNA positive Serology
(IgM: IgG) in
Mean age Mean age DNA positive
No (yr) No (yr) samples
Patients tested for rheumatoid factor 503 23* 214:23
Men 156 45-6 2 30
Women 347 45.0 21 35.5
Source
General practitioners 297 20t 20:20
Rheumatology 118 1 IgM and IgG
Orthopaedics 22 1 IgG only
Others 66 1 IgG only
Blood donor samples 348 1
Men 204 37
Women 144 33
Blood transfusion samples 333 1
Men 117 61
Women 216 52
*P<0.001 when compared with controls. Odds ratio 18 (95% confidence interval 4.2 to 76-7).
tOdds ratio 5 (1-5 to 17); P=0.01 when compared with samples from other sources.
*P<0.001 when compared with 48 sera that were negative for B19 DNA (two of the negative sera
were IgM positive; both patients had an illness typical of B19 infection).
sent from the rheumatology department were: rheu-
matoid arthritis 29%; osteoarthritis 15%; no diagnosis
11%; and 45% miscellaneous disorders.
Comment
Parvovirus infection diagnosed on the basis of
clinical features, IgM, and presence of DNA occurred
frequently in individuals seen in general practice who
were tested for rheumatoid factor. This reflects early
testing for rheumatoid factor in patients who subse-
quently have a short lived illness. A definite clinical
diagnosis was made in only one case, although in most
cases the illness was recognised as viral. Failure to
identify a specific infection in this situation matters
since parvovirus is an important cause of fetal death in
the second trimester4 and many patients were women
of child bearing age. It may also matter for those with
persistent symptoms. B19 is highly infectious and
often asymptomatic.5 Viraemia is rarely detected in
symptomatic individuals except by polymerase chain
reaction, and isolation of patients is unlikely to prevent
further infections.
An epidemic cannot explain the frequency of infec-
tion since only 40 infections were reported to the
infectious disease surveillance unit in Scotland
between December 1992 and February 1993. Two
patients with parvovirus DNA and prolonged symp-
toms were IgM negative. It is difficult, in retrospect, to
be certain that symptoms in these cases were due
to persistent infection. Two patients with an estab-
lished seronegative polyarthritis were IgM positive.
These patients probably developed a coincidental
acute parvovirus infection rather than an exacerbation
of their underlying disease. It does not imply any
relation between B 19 and seronegative arthritis. Parvo-
virus was rarely found in samples sent from the
rheumatology department. Since we relied on clinical
records to assess symptom duration we may have
underestimated chronicitiy. Virus specific IgM, found
in some samples that were negative for B 19 DNA,
showed that we were underestimating the frequency of
infection by polymerase chain reaction alone. It is clear
that serological tests will identify most parvovirus
infections and that this infection is often not recognised
in general practice.
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